 |
Indication & Dosage |
| |
| |
| Oral |
| OVERACTIVE BLADDER |
| Adult:
>18 yr: 2 mg bid (immediate-release preparation) or 4 mg once daily (extended-release preparation), reduce to 1 mg bid if needed to reduce side effects. |
|
| |
|
| Administration |
May be taken with or without food. |
| |
|
| Precautions |
Bladder flow obstruction, GI obstructive disorders, renal or hepatic impairment, autonomic neuropathy, hiatus hernia, risk of decreased GI motility, patients at risk of QT interval prolongation (e.g. electrolyte disturbances, bradycardia, pre-exisiting cardiac disorder). |
| |
|
| Adverse Drug Reactions |
Dry mouth, chest pain, headache, somnolence, fatigue, dry skin, abdominal pain, constipation, dyspepsia, diarrhoea, dizziness, anxiety, wt gain, abnormal vision, dry eyes, paraesthesia, nervousness, urinary retention. |
| |
|
| Interactions |
Increased risk of overdosage with potent CYP3A4 inhibitors e.g. macrolide antibiotics (erythromycin and clarithromycin), azole antifungals (e.g. ketoconazole and itraconazole), protease inhibitors, ciclosporin or vinblastine. Increased risk of torsade de pointes with drugs that prolong the QT interval (e.g. class Ia and class III antiarrhythmics). Increased risk of ''cholinergic neurogenic hypersensitivity'' with centrally acting anticholinesterases (e.g. donepezil, rivastigmine). Increased risk of antimuscarinic side effects with antimuscarinic drugs. |
| |
|
|
|
